Abstract:Osteoporotic fractures, especially in elderly people, represent a health concern as they are associated with increased morbidity and mortality together with an increased economic burden for the society. During the past 20 years a great effort has been done in order to reduce the risk of fracture and many drugs are now available for this purpose, but osteoporosis is still regarded as an inevitable consequences of the aging process. Osteoporotic fractures occur most frequently in the spine and hip and with lower frequency in the wrist, pelvis, and upper arm. They are associated with significant morbidity and those of the hip and spine are also associated with excess mortality. The correct diagnosis and the adequate treatment of osteoporosis can reduce fracture risk. Together with well known anti-resorptive agents (like bisphosphonates, oestrogen and selective oestrogen receptor modulators) in the past few years anabolic therapy with parathyroid hormone (PTH) has become available for the treatment of severe osteoporosis. Human recombinant intact parathyroid hormone (PTH 1-84) and human recombinant PTH peptide 1-34 (Teriparatide) belong to this group of agents.This paper will review PTH actions together with the anabolic effect of PTH 1-84 both in reducing fracture risk and in promoting fracture healing. Although in primary hyperparathyroidism bone catabolism prevails on bone anabolism, PTH remains a potent stimulator of osteoblasts and its anabolic properties can be seen when it is given at a low dosage and intermittently. Intermittent PTH can stimulate bone formation to a greater extent and earlier than bone resorption, thus creating the so called "anabolic window".The TOP study demonstrated that PTH 1-84 is able to reduce the risk of a new fracture in patients with prevalent vertebral fractures, but the same effect was also seen on the incidence of the first fracture in women without fractures at baseline. Moreover PTH produced a continuous increase of bone mineral density, particularly in the cancellous bone. A positive effect of PTH has been described also on fracture healing, consisting both by a shortened time for fracture repair and by an improving of all the parameters of callus formation and development. Although most of the evidence has been obtained in animals some recent studies in humans confirmed, at least in part, these findings. In elderly patients with osteoporosis and fractures PTH treatment may reduce the healing time, improve clinical outcomes and reduce the time of immobilization together with the risk of complications.

Parathyroid hormone related peptides affect diabetic osteoporotic fracture

Parathyroid hormone and its related peptides in bone metabolism

PTH 1-84: bone rebuilding as a target for the therapy of severe osteoporosis

Exogenous Parathyroid Hormone-Related Peptide Promotes Fracture Healing in Lepr(−/−) Mice

The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment

Once-weekly subcutaneous injection of recombinant human parathyroid hormone (1-34) promotes the bone fracture healing in rats

Effect of recombinant human parathyroid hormone on bone fracture healing in the rat observed by micro-CT

Effects of Parathyroid Hormone on Osteoporotic Fracture Healing in Mice via Non-Phospholipases C-Dependent Protein Kinase C Signaling Pathway

Influence of Postoperative Anti-osteoporosis Therapy on Diabetes Patients with Fractures

Intermittent Injection of Parathyroid Hormone Induced Angiogenesis of Callus Via Promoting Vascular Endothelial Growth Factor Expression

Effects of anabolic anti-osteoporotic medicine on osteoporotic fracture healing

Paracrine Effects of Recombinant Human Adiponectin Promote Bone Regeneration

Pilose antler peptide promotes osteoblast proliferation, differentiation and mineralization via the insulin signaling pathway

Parathyroid hormone therapy improves MRSA-infected fracture healing in a murine diabetic model

Therapeutic Effect of Recombinant Human Parathyroid Hormone(1-34) on Osteoporosis of Ovariectomized Rats

A Recombinant Parathyroid Hormone‐Related Peptide Locally Applied in Osteoporotic Bone Defect

Enhancing Bone Regeneration and Osseointegration using rhPTH(1-34) and Dimeric R25CPTH(1-34) in an Osteoporotic Beagle Model

The Effectiveness of Human Parathyroid Hormone and Low-Intensity Pulsed Ultrasound on the Fracture Healing in Osteoporotic Bones

Parathyroid hormone-related peptide (1-34) reduces alveolar bone loss in type 1 diabetic rats

Challenges to Improve Bone Healing under Diabetic Conditions

Effectiveness of teriparatide in in improving healing rates and bone-turnover markers of osteoporotic hip fracture: a meta-analysis